Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle
GeriPal
MAY 19, 2022
It depends on the clinical situation. And really, the best that had ever been looked at, especially in our population and sort of a cancer serious illness population. But we still, regardless of how you do this calculation have to temper it with clinical judgment. Eric: All right. Landmark study. Eric: I got two questions.
139 
Let's personalize your content